Immunosuppressive drug therapy

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 9, 2013, Pages

  Hartono, Choli ^a   Muthukumar, Thangamani ^a   Suthanthiran, Manikkam ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; IMMUNOSUPPRESSIVE AGENT;

ALLOGRAFT; B LYMPHOCYTE; CLASSIFICATION; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGY; PHYSIOLOGY; PLASMA CELL; REVIEW;

ALLOGRAFTS; B-LYMPHOCYTES; COMPLEMENT SYSTEM PROTEINS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PLASMA CELLS; TRANSPLANTATION IMMUNOLOGY;

EID: 84883826118     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a015487     Document Type: Article

References (70)

1. Aull MJ, Dadhania D, Afaneh C, Leeser DB, Hartono C, Lee IB, Serur D, Del Pizzo JJ, Suthanthiran M, Kapur S. 2012. Early corticosteroid withdrawal in recipients of renal allografts: A single-center report of ethnically diverse recipients and recipients of marginal deceased-donor kidneys. Transplantation 94: 837-844.
2. Batista FD, Harwood NE. 2009. The who, how and where of antigen presentation to B cells. Nat Rev Immunol 9: 15-27.
3. Becker YT, Becker BN, Pirsch JD, Sollinger HW. 2004. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 4: 996-1001.
4. Beyers AD, Spruyt LL, Williams AE 1992. Molecular associations between the Tlymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD8 and CD5. Proc Natl Acad Sci 89: 2945-2949.
5. Billingham RE, Brent L, Medawar PB. 1953. Actively acquired tolerance of foreign cells. Nature 172: 603-606.
6. Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, Dolan S, Kano JM, Mahon M, Schnitzler MA, et al. 1999. A randomized, double-blinded comparison of thymoglobulin versus ATGAM for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 67: 1011-1018.
7. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D, Thymoglobulin Induction Study Group. 2006. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 355: 1967-1977.
8. Bromberg J, Cibrik D, Steinberg S, West-Thielke P, Yang H, Erdman J, First R, Holman J. 2011. A phase 2 study to assess the safety and efficacy of alefacept (ALEF) in de novo kidney transplant recipients. American Transplant Congress, Abstract 533.
9. Brown MH, Cantrell DA, Brattsand G, Crumpton MJ, Gullberg M. 1989. The CD2 antigen associates with the T-cell antigen receptor CD3 antigen complex on the surface of human T lymphocytes. Nature 339: 551-553.
10. Busque S, Leventhal J, Brennan DC, Steinberg S, Klintmalm G, Shah T, Mulgaonkar S, Bromberg JS, Vincenti F, Hariharan S, et al. 2009. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: A pilot study in de novo kidney allograft recipients. Am J Transplants. 1936-1945.
11. Busque S, Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, Ling S, Huizinga RB, Meier-Kriesche HU, PROMISE Investigators. 2011. The PROMISE study: A phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant 11: 2675-2684.
12. Dello Strologo L, Guzzo I, Laurenzi C, Vivarelli M, Parodi A, Barbano G, Camilla R, Scozzola F, Amore A, Ginevri F, et al. 2009. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation 88: 417-420.
13. Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, Rial Mdel C, Florman S, Block A, Di Russo G, et al. 2010. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXTstudy). Am Transplant 10: 547-557.
14. European Mycophenolate Mofetil Cooperative Study Group. 1999. Mycophenolate mofetil in renal transplantation: 3-Year results from the placebo-controlled trial. Transplantation 68: 391-396.
15. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, et al. 2008. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 86: 1754-1761.
16. Farasati NA, Shapiro R, Vats A, Randhawa P. 2005. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation 79: 116-118.
17. Fooksman DR, Vardhana S, Vasiliver-Shamis G, Liese J, Blair DA, Waite J, Sacristan C, Victoria GD, Zanin-Zhorov A, Dustin ML. 2010. Functional anatomy of T cell activation and synapse formation. Annu Rev Immunol 28: 79-105.
18. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, et al. 2011. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 3: 85ra46.
19. Friman S, Arns W, Nashan B, Vincenti F, Banas B, Budde K, Cibrik D, Chan L, Klempnauer J, Mulgaonkar S, et al. 2011. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: A randomized phase II study in renal transplant recipients. Am J Transplant 11: 1444-1455.
20. Gelfand EW. 2012. Intravenous immune globulin in autoimmune and inflammatory diseases. JV Engl J Med 367: 2015-2025.
21. Getts DR, Getts MT, McCarthy DP, Chastain EM, Miller SD. 2010. Have we overestimated the benefits of human(ized) antibodies? MAbs 2: 682-694.
22. Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR, Croy R, Holman J, INTAC Study Group. 2011. Alemtuzumab induction in renal transplantation. JV Engl Med 364: 1909-1919.
23. Hardinger KL, Wang CD, Schnitzler MA, Miller BW, Jen-drisak MD, Shenoy S, Lowell JA, Brennan DC. 2002. Prospective, pilot, open-label, short-term study of conversion to leflunomide reverses chronic renal allograft dysfunction. Am J Transplant 2: 867-871.
24. Hardinger KL, Rhee S, Buchanan P, Koch M, Miller B, Enkvetchakul D, Schuessler R, Schnitzler MA, Brennan DC. 2008. A prospective, randomized, double-blinded comparison of thymoglobulin versus ATGAM for induction immunosuppressive therapy: 10 Year results. Transplantation 86: 947-952.
25. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, et al. 2002. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. JV Engl J Med 346: 1692-1698.
26. Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA. 2010. Treatment of polyomavirus infection in kidney transplant recipients: A systemic review. Transplantation 89: 1057-1070.
27. Jordan SC, Tyan D, Stablein D, Mclntosh M, Rose S, Vo A, Toyoda M, Davis C, Shapiro R, Adey D, et al. 2004. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. Am Soc Nephrol 15: 3256-3262.
28. Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, Saidman SL, Shaffer J, Preffer FL, Ding R, Sharma V, et al. 2008. HLA-mismatched renal transplantation without maintenance immunosuppression. JVEng JMed 358: 353-361.
29. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS. 1986. Production of transforming growth factor (i by human T lymphocytes and its potential role in the regulation of T cell growth. Exp Med 163: 1037-1050.
30. Khanna A, Cairns V, Hosenpud JD. 1999. Tacrolimus induces increased expression of transforming growth factorβ 1 in mammalian lymphoid as well as nonlymphoid cells. Transplantation 67: 614-619.
31. Knight DA, Hejmanowski AQ, Dierksheide JE, Williams JW, Chong AS, Waldman WJ. 2001. Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide. Transplantation 71: 170-174.
32. Lebedeva TN, Anikeeva N, Kalams SA, Walker BD, Gaidarov I, Keen JH, Sykulev Y 2004. Major histocompatibility complex class I-intercellular adhesion molecule-1 association on the surface of target cells: Implications for antigen presentation to cytotoxic T lymphocytes. Immunology 113: 460-471.
33. Locke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, King KE, Kraus E, Lees LM, Melancon JK, et al. 2009. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 9: 231-235.
34. Lonze BE, Singer AL, Montgomery RA. 2010. Eculizumab and renal transplantation in a patient with CAPS. NEnglJ Med 362: 1744-1745.
35. Lui SL, Halloran PE 1996. Mycophenolate mofetil in kidney transplantation. Mycophenolate mofetil in kidney transplantation. Curr Opin Nephrol Hypertens 5: 508-513.
36. Marfo K, Ling M, Bao Y, Calder B, Ye B, Hayde N, Greenstein S, Chapochnick-Friedman J, Glicklich D, de Boccardo G, et al. 2012. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation 94: 345-351.
37. Montgomery RA, Lonze BE, King KE, Kraus ES, Kucirka LM, Locke JE, Warren DS, Simpkins CE, Dagher NN, Singer AL, et al. 2011. Desensitization in HLA-incompat-ible kidney recipients and survival. JV Engl J Med 365: 318-326.
38. Mueller TE 2007. Mechanisms of action of thymoglobulin. Transplantation 84: S5-S10.
39. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T, 156 Study Group. 2004. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study. Transplantation 78: 1332-1340.
40. Norman DJ, Vincenti F, de Mattos AM, Barry JM, Levitt DJ, Wedel NI, Maia M, Light SE. 2000. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation 70: 1707-1712.
41. Ortho Multicenter Transplant Study Group. 1985. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. JV Engl J Med 313: 337-342.
42. Pascual J, Zamora J, Galeano C, Royuela A, Quereda C. 2009. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 1: CD005632.
43. Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, Stegall MD. 2009. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 9: 201-209.
44. Pestana JO, Grinyo JM, Vanrenterghem Y, Becker T, Cam-pistol JM, Florman S, Garcia VD, Kamar N, Lang P, Man-fro RC, et al. 2012. Three-year outcomes from BENEFIT-EXT: A phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 12: 630-639.
45. Remuzzi G, Lesti M, Gotti E, Ganeva M, Dimitrov BD, Ene-lordache B, Gherardi G, Donati D, Salvadori M, Sandrini S, et al. 2004. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): A randomised trial. Lancet364: 503-512.
46. Rhen T, Cidlowski JA. 2005. Antiinflammatory action of glucocorticoids-New mechanisms for old drugs. JV Engl Med 353: 1711-1723.
47. Rostaing L, Massari P, Garcia VD, Mancilla-Urrea E, Nainan G, del Carmen Rial M, Steinberg S, Vincenti F, Shi R, Di Russo G, et al. 2011. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: A randomized phase II study. Clin J Am Soc Nephrol 6: 430-439.
48. Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W, Oppenheimer F, Maca J, Hall M, ERL B301 Study Groups. 2004. Enteric-coated mycophenolate sodium is thera-peutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 4:231-236.
49. Sehajpal PK, Sharma VK, Ingulli E, Stenzel KH, Suthan-thiran M. 1993. Synergism between the CD3 antigen-and CD2 antigen-derived signals. Exploration at the level of induction of DNA-binding proteins and characterization of the inhibitory activity of cyclosporine. Transplantation 55: 1118-1124.
50. Sollinger HW. 1995. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60: 225-232.
51. Suthanthiran M. 1990. A novel model for antigen-dependent activation of normal human T cells Transmembrane signaling by crosslinkage of the CD3/T cell receptor-α/β complex with the cluster determinant 2 antigen. JExp Med 171: 1965-1979.
52. Suthanthiran M. 1996. Transplant tolerance: Fooling mother nature. Proc Nail Acad Sci 93: 12072-12075.
53. Suthanthiran M, Garovoy MR. 1983. Immunologic monitoring of the renal transplant recipient. Urol Clin North Am 10: 315-325.
54. Suthanthiran M, Strom TB. 1994. Renal transplantation. N EnglJMed 331: 365-376.
55. + T lymphocytes. Clin Invest 111: 1133-1145.
56. Tyden G, Kumlien G, Genberg H, Sandberg J, Lundgren T, Fehrman I. 2005. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 5: 145-148.
57. Vacca A, Felli MP, Farina AR, Martinotti S, Maroder M, Screpanti I, Meco D, Petrangeli E, Frati L, Gulino A. 1992. Glucocorticoid receptor-mediated suppression of the interleukin 2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med 175: 637-646.
58. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, et al. 2010. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 10: 535-546.
59. Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, Lang P, Mancilla Urrea E, Massari P, Mondragon-Ramirez G, et al. 2012. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 12: 210-217.
60. Vifko S, Margreiter R, Weimar W, Dantal J, Viljoen HG, Li Y, Jappe A, Cretin N, RADB 201 Study Group. 2004. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 78: 1532-1540.
61. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC. 2008. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 359: 242-251.
62. Waldman WJ, Knight DA, Lurain NS, Miller DM, Sedmark DD, Williams JW, Chong AS. 1999. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation 68: 814-825.
63. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. 2004. Interleukin 2 receptor antagonists for renal transplant recipients: A meta-analysis of randomized trials. Transplantation 77: 166-176.
64. Webster AC, Taylor RRS, Chapman JR, Craig JC. 2005. Tacrolimus versus cyclosporine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 4: CD003961.
65. Webster AC, Lee VW, Chapman JR, Craig JC. 2006. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev 2: CD004290.
66. Webster AC, Ruster LP, McGee R, Matheson SL, Higgins GY, Willis NS, Chapman JR, Craig JC. 2010. Interleukin 2 recpetor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 1: CD003897.
67. White NB, Greenstein SM, Cantafio AW, Schechner R, Glicklich D, McDonough P, Pullman J, Mohandas K, Boctor F, Uehlinger J, et al. 2004. Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 78: 772-774.
68. Wuthrich RP, Cicvara S, Ambuhl PM, Binswanger U. 2000. Randomized trial of conversion from mycophenolate mofetil to azathioprine 6 months after renal allograft transplantation. Nephrol Dial Transplant 15:1228-1231.
69. Yabu JM, Ho B, Scandling JD, Vincenti F. 2008. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant 8: 222-227.
70. Zimmerhackl LB, Hofer J, Cortina G, Mark W, Wurzner R, Jungraithmayr TC, Khursigara G, Kliche KO, Radauer W 2010. Prophylactic eculizumab after renal transplantation in atypical hemolyticuremic syndrome. N Engl J Med 362: 1746-1748.